One of the newly discovered antibodies, VHH-Fc, is effective in treating NAFLD, which binds to ANGPTL3 (Angiopoietin-like protein-3) and inhibits its activity [75]. This evidence concerns the gene ANGPTL3 and metabolic dysfunction-associated steatotic liver disease.